Skip to main content

Drug Interactions between immune globulin intravenous and subcutaneous and ravulizumab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

immune globulin intravenous and subcutaneous ravulizumab

Applies to: immune globulin intravenous and subcutaneous and ravulizumab

ADJUST DOSE: Intravenous immunoglobulin (IVIg) treatment has been shown to decrease ravulizumab systemic concentrations. IVIg treatment may interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies such as ravulizumab, which may lead to decreased serum concentrations. Drug interaction studies have not been conducted with ravulizumab in patients treated with IVIg.

MANAGEMENT: The manufacturer advises a supplemental dose of ravulizumab be administered to patients receiving IVIg treatment. For patients weighing 40 kg or more, they recommend a 600 mg supplemental dose of ravulizumab be administered within 4 hours following completion of an IVIg cycle. The manufacturer's product labeling should be consulted for further information.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2019) "Product Information. Ultomiris (ravulizumab)." Alexion Pharmaceuticals Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer